Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 195,000 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $85.14, for a total value of $16,602,300.00. Following the completion of the sale, the insider now directly owns 123,513,247 shares in the company, valued at $10,515,917,849.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Friday, September 15th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00.
  • On Thursday, August 31st, Lilly Endowment Inc sold 180,000 shares of Eli Lilly and stock. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00.
  • On Monday, July 31st, Lilly Endowment Inc sold 220,000 shares of Eli Lilly and stock. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00.

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.95% on Monday, reaching $86.35. 2,718,178 shares of the company were exchanged. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The stock has a market capitalization of $91.10 billion, a price-to-earnings ratio of 37.36 and a beta of 0.34. The firm’s 50 day moving average price is $80.84 and its 200 day moving average price is $82.02.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. Eli Lilly and’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.86 EPS. Equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Lilly Endowment Inc Sells 195,000 Shares of Eli Lilly and Company (LLY) Stock” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/lilly-endowment-inc-sells-195000-shares-of-eli-lilly-and-company-lly-stock/1603784.html.

Hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its stake in Eli Lilly and by 2,628.5% during the 1st quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after purchasing an additional 59,978,664 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after purchasing an additional 9,223,251 shares during the last quarter. Dodge & Cox raised its stake in shares of Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after purchasing an additional 2,181,701 shares during the last quarter. Institutional investors own 75.72% of the company’s stock.

Several research analysts have commented on LLY shares. BMO Capital Markets restated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet raised shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Leerink Swann cut shares of Eli Lilly and from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $93.00 to $90.00 in a research report on Wednesday, July 26th. BidaskClub raised shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Finally, UBS AG downgraded shares of Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a research note on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $88.27.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.